已发表论文

CAR T 细胞用于治疗异基因造血干细胞移植后急性淋巴细胞白血病髓外复发患者:一份病例报告

 

Authors Wang D, Shi R, Wang Q, Li J

Received 2 February 2018

Accepted for publication 25 June 2018

Published 28 September 2018 Volume 2018:11 Pages 6327—6332

DOI https://doi.org/10.2147/OTT.S164430

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Samir Farghaly

Abstract: Philadelphia chromosome-positive (Ph-positive) acute leukemia (ALL) accounts for around one quarter of adult cases of ALL and is usually associated with poor prognosis. The patients still encounter a high rate of relapse even after they receive hematopoietic stem cell transplantation (HSCT). HSCT is considered the established therapy and best option for many malignant ALL cases, however, disease relapse remains the main reason of failure. In recent years, chimeric antigen receptor (CAR) T-cell therapy has become a promising treatment for patients with advanced blood cancers. Here, we report a rare case of a Ph-positive ALL patient with extramedullary relapse in her cervix after receiving allogeneic HSCT. Given the unsatisfactory response to chemotherapy, tyrosine kinase inhibitor (TKI) treatment, and HSCT transplantation, she had received CD19+ CAR T-cell therapy 8 months earlier. The following ultrasound check indicated that her cervix relapse went through significant remission with almost undetectable tumor mass. This case strongly supports the efficacy of CAR T-cell therapy on adult ALL with extramedullary relapse.
Keywords: acute lymphoblastic leukemia, allogeneic hematopoietic stem cell transplantation, CAR T-cell therapy, cervix relapse




Figure 4 Pelvic ultrasound results of the patient before and after CAR T-cell therapy.